Seres Therapeutics, Inc. · NASDAQ:MCRB
Seres Therapeutics — Chardan's Microbiome and Metagenomics Summit (March 2022)
20 slides from Seres Therapeutics's conference presentation, March 2022
Slide 1: Corporate Overview March 2022
Corporate Overview March 2022
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential approval of SER-109 and its status as a first-in-class therapeutic, the timing of a
Slide 3: Pioneering the Development of Microbiome Therapeutics
Pioneering the Development of Microbiome Therapeutics Seres’ mission: To transform the lives of patients worldwide with revolutionary microbiome therapeutics Orally formulated bacterial consortia Encapsulated consortia of commensal bacteria designed to target multiple disease- relevant pathways simu
Slide 4: Strategic Priorities
Strategic Priorities Bring first-in-class Maximize Optimize plans for microbiome opportunities in continued therapeutic to patients infection protection, development in UC with SER-109 BLA based on proven based on SER-287 approval and mechanism of SER- and ongoing SER-301 successful launch for 109 t
Slide 5: Expanding Microbiome Therapeutic Leadership in 2022+
Expanding Microbiome Therapeutic Leadership in 2022+ • SER-109 BLA filing in mid-2022; potential to transform management of recurrent C. difficile infection • Preparing for commercial launch in collaboration with Nestlé Health Science • Build on SER-109 by expanding into additional opportunities in
Slide 6: Strategic Priorities
Strategic Priorities Bring first-in-class Maximize Optimize plans for microbiome opportunities in continued therapeutic to patients infection protection, development in UC with SER-109 BLA based on proven based on SER-287 approval and mechanism of SER- and ongoing SER-301 successful launch for 109 t
Slide 7: Substantial Recurrent C. difficile Infection Market Opportunity
SER-109 Substantial Recurrent C. difficile Infection Market Opportunity Infectious disease caused by toxin-producing bacteria, resulting in diarrhea, abdominal pain, fever and nausea 170,000 episodes per year Leading cause of hospital-acquired infection in the U.S. ‒ ~453K cases of primary CDI withi
Slide 8: Highly Positive SER-109 Phase 3 Study Efficacy Results
SER-109 Highly Positive SER-109 Phase 3 Study Efficacy Results TRIAL DESIGN SER-109 (n = 90) • Multiply recurrent Primary endpoint: Safety C. difficile patients (n=182) • All subjects treated with C. diff. recurrence, at up to 8 weeks follow-up to 24 weeks Approximately 88% standard of care antibiot
Slide 9: Favorable Safety Profile Observed in Phase 3
SER-109 Favorable Safety Profile Observed in Phase 3 • SER-109 was well tolerated, with no treatment-related serious adverse events (SAEs) observed in the active arm, and an adverse event profile comparable to placebo • Overall incidence of patients who experienced AEs was similar between SER-109 an
Slide 10: Phase 3 Data Published in New England Journal of Medicine
SER-109 Phase 3 Data Published in New England Journal of Medicine 10
Slide 11: On Track for BLA Submission in Mid-2022
SER-109 On Track for BLA Submission in Mid-2022 Potential SER-109 Open-label safety study BLA submission FDA review approval and launch • Enrollment completed in • BLA submission mid-2022 • Expect timely review in September after study completion light of Breakthrough Therapy and Orphan • Study has
Slide 12: Well-Positioned to Meet Commercial Demand At Launch and Beyond
Well-Positioned to Meet Commercial Demand At Launch and SER-109 Beyond Seres In-house GMP manufacturing and quality control SER-109 + commercial supply Bacthera collaboration provides redundancy and expands upon existing commercial supply capacity Joint venture between Chr. Hansen and Lonza with off
Slide 13: Seres, Nestlé Health Science SER-109 Co-Commercialization License Agreement - Preparation for Launch
Seres, Nestlé Health Science SER-109 Co-Commercialization SER-109 License Agreement for North America - Preparation for Launch Scaling Market Education Efforts • Broadly engage KOL audience leveraging Seres and NHSc Medical Affairs teams • Develop and deploy payer value proposition with NHSc payer a
Slide 14: Strategic Priorities
Strategic Priorities Bring first-in-class Maximize Optimize plans for microbiome opportunities in continued therapeutic to patients infection protection, development in UC with SER-109 BLA based on proven based on SER-287 approval and mechanism of SER- and ongoing SER-301 successful launch for 109 t
Slide 15: SER-109 Provides Proof of Concept - Infection Protection
SER-109 Provides Proof of Concept - Infection Protection Restructuring the Microbiome and Reducing Pathogens SER-109 bacteria engraft durably & rapidly to restructure microbiome Reduced antimicrobial resistance gene carriage SER-109 Dose Species Engraftment Engrafting Dose Species (#) 10,000 gene ab
Slide 16: Antimicrobial Resistant Infections Are an Urgent Public Health Threat
Antimicrobial Resistant Infections Are an Urgent Public Health Infection Protection Threat Major burden to society Many high risk patient populations Declared “one of the world’s • Allogeneic HSCT recipients at risk for most urgent threats” bloodstream infections • Additional patients with suppresse
Slide 17: SER-155 Phase 1b Study Ongoing
Infection SER-155 Phase 1b Study Ongoing Protection SER-155 Phase 1b study design and objectives Microbiome drug Rationally designed, cultivated product; spore + vegetative type species • ~70 patients in an open-label and a randomized, double-blind, placebo-controlled Stage Phase 1b - enrollment ong
Slide 18: Maximizing the Opportunity in Infection Protection and AMR
Maximizing the Opportunity in Infection Protection and AMR Broadly Target Antimicrobial • Broad preclinical Resistant portfolio Additional Opportunities Infections • Driving to an additional clinical development Autologous HSCT program in 2023 Cancer Neutropenia • Potentially up to 3 Pre-clinical Po
Slide 19: Strategic Priorities
Strategic Priorities Bring first-in-class Maximize Optimize plans for microbiome opportunities in continued therapeutic to patients infection protection, development in UC with SER-109 BLA based on proven based on SER-287 approval and mechanism of SER- and ongoing SER-301 successful launch for 109 t
Slide 20: Well-Capitalized to Extend Microbiome Therapeutic Leadership
Well-Capitalized to Extend Microbiome Therapeutic Leadership SER-109 BLA approval and successful launch for recurrent CDI SER-109: anticipate BLA filing in mid 2022 Opportunities in infection protection As of Dec. 31, 2021: $291M in cash, cash SER-155: Phase 1b initiated and first patient enrolled e
Seres Therapeutics — Chardan's Microbiome and Metagenomics Summit (March 2022) on 6ix